Skip to main content

Advertisement

Table 3 Number of patients presenting with either anti- Factor IIa (thrombin) inhibitor, anti-Factor V (FV) inhibitor, or both

From: Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety

  Bleeding Cases
N = 32
Non-Bleeding Cases
N = 32
Total
N = 64
Inhibitor Type n (%) n (%) n (%)
FIIa 4 (13) 4 (12) 8 (12)
FV 17 (53) 15 (47) 32 (50)
FIIa and FV 11 (34) 13 (41) 24 (38)
  1. Sorted by clinical presentation and contained reports of a surgical setting where known or presumed bovine thrombin exposure occurred [335].